A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : RTX / response to rituximab

[Related PubMed/MEDLINE]
Total Number of Papers: 21
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   RTX  (>> Co-occurring Abbreviation)
Long Form:   response to rituximab
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibody Diseases. AQP4, MOG
2019 Smoking and response to rituximab in rheumatoid arthritis: results from an international European collaboration. ACPA, CI, csDMARDs, EULAR, HAQ, OR, RA, RF
2017 Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis. EULAR, IFN, RA, STAT4, TYK2
2016 Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis. anti-CCP, CI, ELISA, EULAR, Ig, IL, OR, RA, RF
2015 Body Mass Index and response to rituximab in rheumatoid arthritis. BMI
2015 Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies. AIHA, CAD, CR, ORR
2015 Rituximab in the treatment of refractory scleritis in patients with granulomatosis with polyangiitis (Wegener's). BVAS-WG, GPA, PR-3 ANCA
2014 High anti-CCP antibody titres predict good response to rituximab in patients with active rheumatoid arthritis. RA
2014 Influence of gender on response to rituximab in patients with rheumatoid arthritis: results from the Autoimmunity and Rituximab registry. AIR, EULAR
10  2014 The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study. EULAR, RA, TNF
11  2014 Use of whole-blood transcriptomic profiling to highlight several pathophysiologic pathways associated with response to rituximab in patients with rheumatoid arthritis: data from a randomized, controlled, open-label trial. RA
12  2014 [Absence of response to rituximab in patients with refractory primary immune thrombocytopenia]. ELISA, FCM, ITP, PB, Tm
13  2013 CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis. EULAR, OR, RA
14  2013 Low- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study. alpha1M, CR, FE, LR, MN, NR, PR, RBP, Ualpha1M
15  2013 Predictive factors of rituximab response in rheumatoid arthritis: results from a French university hospital. anti-CCP, EBV, OR, RA, RF
16  2013 Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis. ABT, RA, RF, TCZ
17  2013 The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockers. anti-TNF, BLyS, ORs, RA
18  2011 Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis. BAFF-R, MTX, RA
19  2010 [Optimizing rheumatoid arthritis treatment with rituximab--individualized patient approach]. RA
20  2009 NK and NKT cell dynamics after rituximab therapy for systemic lupus erythematosus and rheumatoid arthritis. RA, SLE
21  2009 Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. anti-CCP, DAS28, EULAR